Should we modify the current FIGO staging system for stage IIIC ovarian cancer?

Ovarian cancer is the leading cause of death among female re-productive tract cancers and the fifth most common overall cause of cancer death among women, with 22,430 newly diag-nosed cases and 15,280 cause-specific deaths estimated in the United States in 2007.1 In Korea, it marks the eighth most common female cancer (3.6%) among 43,627 new total fe-male cancer cases, and cancer death (3.1%) among 24,014 cause-specific deaths.2 In 1983, Chen et al. reported the incidence of retro-peritoneal lymph node metastases in untreated cases of ovar-ian carcinoma. The incidence of positive para-aortic nodes i